



A green chemical approach toward the synthesis of 7,9-diaryl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylates catalyzed by *p*-toluenesulfonic acid under focused microwave irradiation

J. Thanusu , V. Kanagarajan & M. Gopalakrishnan

To cite this article: J. Thanusu , V. Kanagarajan & M. Gopalakrishnan (2012) A green chemical approach toward the synthesis of 7,9-diaryl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylates catalyzed by *p*-toluenesulfonic acid under focused microwave irradiation, Green Chemistry Letters and Reviews, 5:1, 65-72, DOI: [10.1080/17518253.2011.581699](https://doi.org/10.1080/17518253.2011.581699)

To link to this article: <https://doi.org/10.1080/17518253.2011.581699>



Copyright Taylor and Francis Group, LLC



Published online: 09 Jun 2011.



Submit your article to this journal [↗](#)



Article views: 684



View related articles [↗](#)



Citing articles: 2 View citing articles [↗](#)

RESEARCH LETTER


A green chemical approach toward the synthesis of 7,9-diaryl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylates catalyzed by *p*-toluenesulfonic acid under focused microwave irradiation

J. Thanusu, V. Kanagarajan and M. Gopalakrishnan*

Synthetic Organic Chemistry Laboratory, Department of Chemistry, Annamalai University, Annamalai Nagar 608002, Tamil Nadu, India

(Received 20 January 2010; final version received 11 April 2011)

In the present work, a new series of novel 7,9-diaryl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylates **11–20** was synthesized by the reaction of 6-carbethoxy-3,5-diarylcyclohex-2-enones **1–10** with ethylene diamine in the presence of *p*-toluenesulfonic acid (*p*-TSA) in solvent-free conditions under focused microwave irradiation (MWI) and were characterized by melting point, elemental analysis, MS, FT-IR, one-dimensional NMR (^1H , D_2O exchanged ^1H & ^{13}C), and two-dimensional Heteronuclear Multiple Quantum Coherence (HMQC) spectroscopic data.



Keywords: 7,9-diaryl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylates; 6-carbethoxy-3,5-diarylcyclohex-2-enones; ethylene diamine; *p*-toluenesulfonic acid; focused microwave irradiation

Introduction

Imidazolidine is a nitrogen-containing heterocycle derived from imidazole. Generally, imidazolidines are synthesized by the treatment of aldehydes with ethylene diamine in high yields of crystalline solids (1). Condensation of cyclohexanone with ethylene diamine yields 1,4-diazaspiro[4.5]decane, a *N,N'*-unsubstituted imidazolidine (2). A convenient synthesis of unsymmetrical and optically active imidazolidines in good yields is reported via Mannich reaction (3). Recently, imidazolidine derivatives are synthesized by sono-synthetic method (4). Spiro imidazolidine–oxazolidine derivatives are used as an intermediate in the aziridination reaction (5).

In recent decades, the synthesis of imidazolidine derivatives has attracted considerable attention because these heterocycles exhibit a wide range of pharmacological activities (6, 7). In spite of the wide applications as drugs and drug-intermediates, derivatives of imidazolidine-2-thione, namely azolothiazines and benzimidazolidine-2-thiones play a potent role

in medicinal chemistry (8–10). A novel series of five-membered imidazolidine-2,4-dione derivatives act as HIV protease inhibitors, and they exhibit potent activity against both wild-type virus and a mutant strain (A17) that is highly resistant to lopinavir (11).

The present study describes the use of 6-carbethoxy-3,5-diarylcyclohex-2-enones (12), an intermediate with three versatile functional groups, i.e. ketone, olefin, and ester for the synthesis of imidazolidine derivatives, since in recent years there has been a great deal of interest in exploiting more than one proximal functional groups for designing novel structures capable of performing a variety of functions. In continuation with our earlier work on the green synthesis of structurally diverse biologically active hybrid heterocyclic ring systems and as part of our ongoing research program (13–23), we planned to design imidazolidine derivatives bearing a cyclohexene substituent on the carbon between the nitrogen centers to give a new series of heterocycles, namely 7,9-diaryl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl

*Corresponding author. Email: profmgk@yahoo.co.in

carboxylates **11–20** since imidazolidine derivatives are known pharmacophores in several structure-based drug design approaches (24–28).


Results and discussion

Condensation of appropriate acetophenone and appropriate benzaldehyde in the presence of sodium hydroxide yields the respective 1,3-diaryl-prop-2-en-1-ones which on treatment with ethyl acetoacetate in the presence of sodium ethoxide gives 6-carbethoxy-3,5-diarylcyclohex-2-enones **1–10** by Knoevenagel reaction (Scheme 1). Synthesis of novel 7,9-diaryl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylates **11–20** was carried out by the reaction of 6-carbethoxy-3,5-diarylcyclohex-2-enones **1–10** with ethylene diamine in the presence of *p*-toluenesulfonic acid (*p*-TSA) in solvent-free conditions under focused microwave irradiation (MWI), since the applications of microwave technology to rapid synthesis of biologically significant heterocyclic molecules under solvent-free conditions are very promising and numerous and have recently been recognized as a useful tool for a drug-discovery program especially in combinatorial chemistry (14–19). The reactions were performed at 120°C and 4 bar pressure for 5 min. After completion of the reaction as indicated by the TLC, the reaction mixture was poured into ice water. The mixture was extracted with dichloromethane and washed with 10% sodium bicarbonate solution, finally washed with distilled water, concentrated in rotary evaporator and purified


by flash column chromatography using toluene:ethyl acetate (8:2) as eluent.

The synthetic route for the formation of compounds **11–20** is given in Scheme 2. The physical and analytical data are given in Table 1. The structures of all the synthesized compounds **11–20** are discussed with the help of m.p.'s, elemental analysis, FT-IR, MS, one-dimensional ^1H NMR, D_2O exchanged ^1H NMR, ^{13}C NMR, and two-dimensional Heteronuclear Multiple Quantum Coherence (HMQC) spectra. In order to investigate the spectral assignments, 7,9-diphenyl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylate **11** was chosen as a representative compound.

FT-IR spectrum of **11** shows characteristic absorption frequencies in the region of $3267\text{--}3528\text{ cm}^{-1}$, suggesting the presence of NH stretching frequency. The absorption frequency at 1738 cm^{-1} is due to the presence of carbonyl stretching of ester group. Moreover, the absorption frequency at 1607 cm^{-1} is due to the presence of C = C stretching. The presence of band at 1445 cm^{-1} (C–N) is more evident for the formation of **11**. The observed NH stretching, C = C stretching, and C = O of ester functional group absorption bands, all support for the formation of compound **11**. The mass spectrum of **11** shows molecular ion peak at m/z 363($\text{M}^{\bullet} + 1$) which is consistent with the proposed structure of **11**. Elemental analysis [C_{cal} 76.21, C_{obs} 76.11; H_{cal} 7.23, H_{obs} 7.15; N_{cal} 7.73, N_{obs} 7.63] is consistent with the molecular formula [$\text{C}_{23}\text{H}_{26}\text{N}_2\text{O}_2$] of **11**. The assignments of signals in ^1H NMR spectrum have been done based on total widths, position, and spin



Scheme 1. Synthesis of ethyl 4,6-diaryl-2-oxocyclohex-3-enecarboxylates.



Scheme 2. Synthesis of novel 7,9-diaryl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylates.


multiplicities. A singlet observed at 6.54 ppm is conveniently assigned to H-10 proton of cyclohexene moiety. Two multiplets that appeared in the region of 2.97–3.02 ppm is due to methylene protons H-8 of cyclohexene moiety. Another multiplet observed in the range 3.04–3.22 ppm is due to benzylic proton H-7. The methyl protons (CH_3) of ester group appeared as a triplet, centered at 0.90 ppm. The methylene protons (CH_2) of ester group observed as a quartet, centered at 3.90 ppm. A signal observed as multiplet between 3.51 and 3.67 ppm corresponding to one proton is unambiguously assigned to H-6 proton. The two NH protons of imidazolidine moiety were observed as broad singlet at 5.98 ppm corresponding to two protons. In addition, methylene protons (H-2, H-3) at C-2 and C-3 of

imidazolidine moiety observed as a multiplet at around 4.02–4.13 ppm. The aromatic protons appeared as a multiplet in the range 7.10–7.79 ppm. The presence of labile $-\text{NH}$ protons at positions 1 and 4 is confirmed by recording the ^1H NMR spectrum after adding D_2O . The peak at 5.98 ppm due to two NH protons at positions 1 and 4 have disappeared in the D_2O exchanged ^1H NMR spectrum.

In ^{13}C NMR spectrum, six resonances in the aliphatic region 13.7, 58.7, 49.3, 59.9, 35.2, and 43.8 ppm have been observed (with the help of HMQC the individual assignment could be carried out). The remaining ^{13}C resonances at 169.2, 137.3, and 141.4 ppm are due to quaternary carbons. The ^{13}C resonance at 121.9 ppm may be due to C-10 carbon.

Table 1. Physical and analytical data for the title compounds 11–20.

Compounds	X	Y	M.P. (°C)	Yield (%)	Elemental analysis (%)			m/z (M + 1) ⁺ Molecular formula
					C Found (calculated)	H Found (calculated)	N Found (calculated)	
11	H	H	77	95	76.11 (76.21)	7.15 (7.23)	7.63 (7.73)	363 $\text{C}_{23}\text{H}_{26}\text{N}_2\text{O}_2$
12	H	Cl	100	93	69.48 (69.60)	6.24 (6.35)	6.95 (7.06)	397, 399 $\text{C}_{23}\text{H}_{25}\text{N}_2\text{O}_2\text{Cl}$
13	H	F	65	92	72.52 (72.61)	6.57 (6.62)	7.23 (7.36)	381 $\text{C}_{23}\text{H}_{25}\text{N}_2\text{O}_2\text{F}$
14	H	CH_3	117	90	76.49 (76.56)	7.43 (7.50)	7.32 (7.44)	377 $\text{C}_{24}\text{H}_{28}\text{N}_2\text{O}_2$
15	H	OCH_3	112	93	73.33 (73.44)	7.10 (7.19)	7.01 (7.14)	393 $\text{C}_{24}\text{H}_{28}\text{N}_2\text{O}_3$
16	Cl	H	68	91	69.52 (69.60)	6.30 (6.35)	6.97 (7.06)	397, 399 $\text{C}_{23}\text{H}_{25}\text{N}_2\text{O}_2\text{Cl}$
17	OCH_3	H	65	92	73.32 (73.44)	7.11 (7.19)	7.03 (7.14)	393 $\text{C}_{24}\text{H}_{28}\text{N}_2\text{O}_3$
18	Cl	CH_3	73	93	70.04 (70.15)	6.53 (6.62)	6.78 (6.82)	411, 413 $\text{C}_{24}\text{H}_{27}\text{N}_2\text{O}_2\text{Cl}$
19	OCH_3	Cl	69	95	67.42 (67.52)	6.25 (6.37)	6.51 (6.56)	427, 429 $\text{C}_{24}\text{H}_{27}\text{N}_2\text{O}_3\text{Cl}$
20	Cl	OCH_3	99	93	67.44 (67.52)	6.29 (6.37)	6.48 (6.56)	427, 429 $\text{C}_{24}\text{H}_{27}\text{N}_2\text{O}_3\text{Cl}$

Table 3. Comparison of the reaction of ethyl 6-(4-chlorophenyl)-4-(4-methoxyphenyl)-2-oxocyclohex-3-ene carboxylate and ethylene diamine under various *p*-TSA loadings and reaction conditions.

Entry ^a	<i>p</i> -TSA Catalyst (mol%)	Reaction conditions	Time (min)	Conversion (%) ^b
1	30	Solvent-free, 90°C	45	25
2	20	Solvent-free, 90°C	45	20
3	10	Solvent-free, 90°C	45	20
4	0	Microwave, 4 bar pressure, 120°C	10	45
5	30	Microwave, DMF, 4 bar pressure, 120°C	5	30
6	20	Microwave, DMF, 4 bar pressure, 120°C	5	25
7	10	Microwave, DMF, 4 bar pressure, 120°C	5	20
8	30	Microwave, solvent-free, 2 bar pressure, 120°C	5	35
9	20	Microwave, solvent-free, 2 bar pressure, 120°C	5	60
10	10	Microwave, solvent-free, 2 bar pressure, 120°C	5	70
11	30	Microwave, solvent-free, 4 bar pressure, 120°C	5	40
12	20	Microwave, solvent-free, 4 bar pressure, 120°C	5	90
13	10	Microwave, solvent-free, 4 bar pressure, 120°C	5	95

^aAll reactions were run using 0.01 mol of ethyl 6-(4-chlorophenyl)-4-(4-methoxyphenyl)-2-oxocyclohex-3-ene carboxylate and 0.01 mol of ethylene diamine.

^bIsolated yield.

Experimental

Chemistry

General remarks

We used TLC (eluent: toluene–ethylacetate 8:2) to assess the reactions and the purity of the products. All the reported melting points were taken in open capillaries and are uncorrected. IR spectra were recorded in KBr (pellet forms) on a Thermo Nicolet-Avatar–330 FT-IR spectrophotometer and noteworthy absorption values (cm^{-1}) alone were listed. One-dimensional ^1H and ^{13}C NMR spectra were recorded at 400 MHz and 100 MHz, respectively, on Bruker AMX 400 NMR spectrometer using $\text{DMSO-}d_6$ as solvent and tetramethylsilane (TMS) as internal standard. Two-dimensional HMQC spectrum was recorded at 500 MHz on Bruker DRX 500 NMR spectrometer using $\text{DMSO-}d_6$ as solvent and TMS as internal standard. The electron spray impact (ESI) positive (+ve) mass (MS) spectra were recorded on a Bruker Daltonics LC–MS spectrometer. Satisfactory microanalysis was obtained on a Carlo Erba 1106 CHN analyzer. Gyan Easiflash Flash column chromatography system, Italy, was used for flash column chromatography. BIOTAGE

Initiator microwave synthesizer, Sweden, a scientific microwave oven, was used for the irradiation. By adopting the literature procedure, 6-carbomethoxy-3,5-diarylcyclohex-2-enone **1–10** (**8**) were prepared.

General procedure for the synthesis of 7,9-diaryl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylates **11–20**

In a 10 mL pyrex glass tube was placed respective 6-carbomethoxy-3,5-diarylcyclohex-2-enones (0.01 mol), ethylene diamine (0.01 mol), and catalytic amount of *p*-TSA (0.172 g, 0.001 mol). The top of glass tube was closed with teflon cover and it was placed in a teflon outer jacket and then the reaction tube was placed into the holder in the microwave cavity. The sample was irradiated under focused monomode irradiation at 120°C for 5 min. at 4 bar pressure. After allowing the mixture to cool to room temperature, the reaction vessel was opened and the contents were poured into ice cold water. The organic material was extracted with ethylacetate. The organic layer was washed with 10% sodium hydrogen carbonate, brine solution and then excess of water and dried over anhydrous sodium sulfate. After

evaporation of the ethylacetate under vacuum, solid mass obtained was subjected to flash column chromatography using toluene–ethylacetate as eluent.

Spectroscopic data

7,9-Diphenyl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylate 11

IR (KBr) (cm^{-1}): 3448, 3388, 3175, 3054, 3022, 2972, 2931, 2837, 1738, 1599, 1447, 1027, 827, 758, 698; ^1H NMR (δ ppm): 0.89–0.90 (*t*, 3H, ester CH_3); 2.97–3.02 (*m*, 2H, H_8), 3.04–3.22 (*m*, 1H, H_7), 3.51–3.67 (*m*, 1H, H_6), 3.87–3.92 (*q*, 2H, ester CH_2), 4.02–4.13 (*m*, 4H, imidazolidine 2CH_2), 5.98 (*s*, 2H, imidazolidine 2NH), 6.54 (*s*, 1H, H_{10}), 7.10–7.79 (*m*, 10H, Ar–H's); in the D_2O exchanged ^1H NMR spectrum, singlet at 5.98 ppm which resonates due to 2NH 's of imidazolidine moiety disappeared; ^{13}C NMR (δ ppm): 13.7 ester CH_3 , 35.2 C-7, 43.8 C-8, 49.3 C-2 & C-3, 80.1 C-5, 58.7 ester CH_2 , 59.9 C-6, 121.9 C-10, 122.88–130.4 Ar–C's, 137.3, 141.4 *ipso*-C, 169.2 C = O.

7-(4-Chlorophenyl)-9-phenyl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylate 12

IR (KBr) (cm^{-1}): 3535, 3437, 3382, 3295, 3065, 2978, 2924, 2847, 1735, 1601, 1445, 1018, 824, 758, 693; ^1H NMR (δ ppm): 0.92–0.93 (*t*, 3H, ester CH_3); 2.97–3.07 (*m*, 2H, H_8), 3.10–3.14 (*m*, 1H, H_7), 3.57–3.76 (*m*, 1H, H_6), 3.89–3.94 (*q*, 2H, ester CH_2), 4.02–4.15 (*m*, 4H, imidazolidine 2CH_2), 6.12 (*s*, 2H, imidazolidine 2NH), 6.55 (*s*, 1H, H_{10}), 7.13–7.79 (*m*, 9H, Ar–H's); in the D_2O exchanged ^1H NMR spectrum, singlet at 6.12 ppm which resonates due to 2NH 's of imidazolidine moiety disappeared; ^{13}C NMR (δ ppm): 13.7 ester CH_3 , 34.9 C-7, 43.1 C-8, 48.4 C-2 & C-3, 80.2 C-5, 58.5 ester CH_2 , 60.0 C-6, 121.9 C-10, 122.88–140.4 Ar–C's, 159.1, 160.4 *ipso*-C, 169.0 C = O.

7-(4-Fluorophenyl)-9-phenyl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylate 13

IR (KBr) (cm^{-1}): 3519, 3388, 3262, 3186, 3058, 2977, 2930, 2863, 1739, 1604, 1443, 1023, 832, 758, 694; ^1H NMR (δ ppm): 0.88–0.90 (*t*, 3H, ester CH_3); 2.74–2.94 (*m*, 2H, H_8), 2.98–3.13 (*m*, 1H, H_7), 3.56–3.88 (*m*, 1H, H_6), 3.87–3.92 (*q*, 2H, ester CH_2), 3.95–4.13 (*m*, 4H, imidazolidine 2CH_2), 6.02 (*s*, 2H, imidazolidine 2NH), 6.57 (*s*, 1H, H_{10}), 6.83–7.94 (*m*, 9H, Ar–H's); in the D_2O exchanged ^1H NMR spectrum, singlet at 6.02 ppm which resonates due to 2NH 's of imidazolidine moiety disappeared; ^{13}C NMR (δ ppm): 13.7 ester CH_3 , 35.2 C-7, 42.9 C-8, 48.4 C-2 & C-3, 80.2 C-5, 59.8 ester CH_2 , 61.0 C-6, 122.3

C-10, 113.1–136.1 Ar–C's, 157.8, 158.2 *ipso*-C, 169.1 C = O.

7-(4-Methylphenyl)-9-phenyl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylate 14

IR (KBr) (cm^{-1}): 3454, 3399, 3267, 3054, 3038, 2981, 2921, 2863, 1739, 1604, 1023, 832, 758, 694; ^1H NMR (δ ppm): 0.92–0.96 (*t*, 3H, ester CH_3); 2.26 (*s*, 3H, CH_3 of phenyl ring), 2.72–2.93 (*m*, 2H, H_8), 2.97–3.12 (*m*, 1H, H_7), 3.56–3.76 (*m*, 1H, H_6), 3.87–3.93 (*q*, 2H, ester CH_2), 4.00–4.09 (*m*, 4H, imidazolidine 2CH_2), 5.94 (*s*, 2H, imidazolidine 2NH), 6.53 (*s*, 1H, H_{10}), 6.88–7.91 (*m*, 9H, Ar–H's); in the D_2O exchanged ^1H NMR spectrum, singlet at 5.94 ppm which resonates due to 2NH 's of imidazolidine moiety disappeared; ^{13}C NMR (δ ppm): 13.7 ester CH_3 , 20.5 CH_3 of phenyl ring, 35.3 C-7, 43.3 C-8, 48.9 C-2 & C-3, 80.2 C-5, 59.8 ester CH_2 , 60.9 C-6, 121.9 C-10, 122.8–138.4 Ar–C's, 159.2, 160.0 *ipso*-C, 169.1 C = O.

7-(4-methoxyphenyl)-9-phenyl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylate 15

IR (KBr) (cm^{-1}): 3524, 3424, 3267, 3054, 2989, 2929, 2830, 1739, 1445, 1607, 1033, 832, 760, 694; ^1H NMR (δ ppm): 0.92–0.94 (*t*, 3H, ester CH_3); 2.69–2.93 (*m*, 2H, H_8), 2.97–3.12 (*m*, 1H, H_7), 3.58–3.64 (*m*, 1H, H_6), 3.72 (*s*, 3H, OCH_3 of phenyl ring), 3.88–3.93 (*q*, 2H, ester CH_2), 3.96–4.36 (*m*, 4H, imidazolidine 2CH_2), 5.94 (*s*, 2H, imidazolidine 2NH), 6.61 (*s*, 1H, H_{10}), 6.85–7.78 (*m*, 9H, Ar–H's); in the D_2O exchanged ^1H NMR spectrum, singlet at 5.94 ppm which resonates due to 2NH 's of imidazolidine moiety disappeared; ^{13}C NMR (δ ppm): 13.7 ester CH_3 , 35.4 C-7, 43.0 C-8, 48.5 C-2 & C-3, 80.3 C-5, 54.9 OCH_3 of phenyl ring, 59.8 ester CH_2 , 60.9 C-6, 121.9 C-10, 113.1–158.2 Ar–C's, 159.3, 160.6 *ipso*-C, 169.2 C = O.

9-(4-chlorophenyl)-7-phenyl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylate 16

IR (KBr) (cm^{-1}): 3524, 3386, 3175, 3059, 3029, 2978, 2927, 2858, 1738, 1448, 1584, 1013, 824, 762, 699; ^1H NMR (δ ppm): 0.90–0.91 (*t*, 3H, ester CH_3); 2.71–2.97 (*m*, 2H, H_8), 3.00–3.15 (*m*, 1H, H_7), 3.60–3.78 (*m*, 1H, H_6), 3.88–3.93 (*q*, 2H, ester CH_2), 3.97–4.13 (*m*, 4H, imidazolidine 2CH_2), 6.08 (*s*, 2H, imidazolidine 2NH), 6.59 (*s*, 1H, H_{10}), 6.88–7.79 (*m*, 9H, Ar–H's); in the D_2O exchanged ^1H NMR spectrum, singlet at 6.08 ppm which resonates due to 2NH 's of imidazolidine moiety disappeared; ^{13}C NMR (δ ppm): 14.2 ester CH_3 , 35.1 C-7, 43.0 C-8,

48.3 C-2 & C-3, 80.2 C-5, 59.9 ester CH₂, 61.0 C-6, 122.8 C-10, 114.3–137.6 Ar-C's, 141.4, 159.2 *ipso*-C, 168.9 C = O.

9-(4-methoxyphenyl)-7-phenyl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylate 17

IR (KBr) (cm⁻¹): 3450, 3444, 3065, 3033, 2924, 2852, 1736, 1605, 1447, 1037, 757, 695; ¹H NMR (δ ppm): 0.90–0.92 (*t*, 3H, ester CH₃); 2.72–2.98 (*m*, 2H, H₈), 3.01–3.16 (*m*, 1H, H₇), 3.59–3.71 (*m*, 1H, H₆), 3.73 (*s*, 3H, OCH₃ of phenyl ring), 3.88–3.93 (*q*, 2H, ester CH₂), 3.96–4.08 (*m*, 4H, imidazolidine 2CH₂), 5.93 (*s*, 2H, imidazolidine 2NH), 6.51 (*s*, 1H, H₁₀), 6.83–7.81 (*m*, 9H, Ar-H's); In the D₂O exchanged ¹H NMR spectrum, singlet at 5.93 ppm which resonates due to 2NH's of imidazolidine moiety disappeared; ¹³C NMR (δ ppm): 13.7 ester CH₃, 36.0 C-7, 43.7 C-8, 49.2 C-2 & C-3, 80.2 C-5, 54.3 OCH₃ of phenyl ring, 59.9 ester CH₂, 61.0 C-6, 122.3 C-10, 116.2–141.4 Ar-C's, 157.8, 159.2 *ipso*-C, 169.0 C = O.

9-(4-chlorophenyl)-7-(4-methylphenyl)-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylate 18

IR (KBr) (cm⁻¹): 3459, 3386, 3273, 3169, 3049, 2983, 2923, 2856, 1739, 1612, 1447, 1013, 817, 744, 711; ¹H NMR (δ ppm): 0.92–0.94 (*t*, 3H, ester CH₃); 2.27 (*s*, 3H, CH₃ of phenyl ring), 2.75–2.98 (*m*, 2H, H₈), 2.98–3.15 (*m*, 1H, H₇), 3.57–3.77 (*m*, 1H, H₆), 3.87–3.93 (*q*, 2H, ester CH₂), 4.00–4.10 (*m*, 4H, imidazolidine 2CH₂), 6.00 (*s*, 2H, imidazolidine 2NH), 6.55 (*s*, 1H, H₁₀), 6.89–7.98 (*m*, 8H, Ar-H's); in the D₂O exchanged ¹H NMR spectrum, singlet at 6.00 ppm which resonates due to 2NH's of imidazolidine moiety disappeared; ¹³C NMR (δ ppm): 14.2 ester CH₃, 20.5 CH₃ of phenyl ring, 35.5 C-7, 43.2 C-8, 48.8 C-2 & C-3, 80.2 C-5, 59.8 ester CH₂, 61.0 C-6, 122.2 C-10, 123.2–154.5 Ar-C's, 157.8, 159.2 *ipso*-C, 169.0 C = O.

7-(4-chlorophenyl)-9-(4-methoxyphenyl)-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylate 19

IR (KBr) (cm⁻¹): 3442, 3393, 3284, 3065, 2962, 2923, 2850, 1738, 1598, 1457, 1140, 826, 718; ¹H NMR (δ ppm): 0.92–0.94 (*t*, 3H, ester CH₃); 2.77–2.98 (*m*, 2H, H₈), 2.77–2.98 (*m*, 1H, H₇), 3.48–3.75 (*m*, 1H, H₆), 3.77 (*s*, 3H, OCH₃ of phenyl ring), 3.88–3.93 (*q*, 2H, ester CH₂), 4.01–4.06 (*m*, 4H, imidazolidine 2CH₂), 5.96 (*s*, 2H, imidazolidine 2NH), 6.55 (*s*, 1H, H₁₀), 6.96–7.82 (*m*, 8H, Ar-H's); in the D₂O exchanged ¹H NMR spectrum, singlet at 5.96 ppm which resonates due to 2NH's of imidazolidine moiety disappeared; ¹³C NMR (δ ppm): 13.7 ester

CH₃, 36.0 C-7, 43.7 C-8, 49.2 C-2 & C-3, 80.2 C-5, 55.2 OCH₃ of phenyl ring, 59.8 ester CH₂, 60.9 C-6, 119.9 C-10, 120.9–158.5 Ar-C's, 159.6, 161.2 *ipso*-C, 169.2 C = O.

9-(4-chlorophenyl)-7-(4-methoxyphenyl)-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylate 20

IR (KBr) (cm⁻¹): 3453, 3393, 3262, 3065, 2951, 2927, 2830, 1738, 1608, 1456, 1032, 824, 749, 711; ¹H NMR (δ ppm): 0.92–0.94 (*t*, 3H, ester CH₃); 2.87–3.09 (*m*, 2H, H₈), 3.12–3.19 (*m*, 1H, H₇), 3.59–3.70 (*m*, 1H, H₆), 3.71 (*s*, 3H, OCH₃ of phenyl ring), 3.87–3.92 (*q*, 2H, ester CH₂), 4.05–4.20 (*m*, 4H, imidazolidine 2CH₂), 5.96 (*s*, 2H, imidazolidine 2NH), 6.55 (*s*, 1H, H₁₀), 7.24–7.91 (*m*, 8H, Ar-H's); in the D₂O exchanged ¹H NMR spectrum, singlet at 5.96 ppm which resonates due to 2NH's of imidazolidine moiety disappeared; ¹³C NMR (δ ppm): 14.3 ester CH₃, 35.6 C-7, 43.1 C-8, 48.4 C-2 & C-3, 79.9 C-5, 55.2 OCH₃ of phenyl ring, 59.9 ester CH₂, 61.0 C-6, 119.9 C-10, 120.9–158.4 Ar-C's, 159.7, 161.2 *ipso*-C, 169.1 C = O.

Conclusion

To conclude, we have proposed an efficient method for the synthesis of novel 7,9-diaryl-1,4-diazaspiro[4.5]-deca-9-ene-6-ethyl carboxylates **11–20** by the reaction of 6-carbethoxy-3,5-diarylcyclohex-2-enones **1–10** with ethylene diamine in the presence of *p*-TSA in solvent-free conditions under focused MWI, and their structures were characterized by their spectral and analytical data. The advantages of the present reaction procedure include short reaction times for product formation, easy workup, clean reaction profiles, high yields, etc.

Acknowledgements

Authors are thankful to NMR Research Centre, Indian Institute of Science, Bangalore, for recording spectra and to M/s Micro devices, Chennai, for providing microwave oven. V. Kanagarajan is grateful to Council of Scientific and Industrial Research (CSIR), New Delhi, Republic of India, for providing financial support in the form of CSIR-Senior Research Fellowship (SRF) in Organic Chemistry. J. Thanusu is highly thankful to Annamalai University authorities for providing University Studentship.

References

- (1) Wanzlick, H.W.; Lochel, W. *Chem. Ber.* **1963**, *86*, 1463–1464.
- (2) Bergmann, E.D.; Meeron, E.; Hirschberg, Y.; Pinchas, S. *Rec. Trav. Chim.* **1952**, *11*, 200–202.

- (3) Katritzky, A.R.; Suzuki, K.; He, H.Y. *J. Org. Chem.* **2002**, *67*, 3109–3114.
- (4) Entezari, M.H.; Asghari, A.; Hadizadeh, F. *Ultrasonics Sonochem.* **2008**, *15*, 119–123.
- (5) Disadee, W.; Ishikawa, T.; Kawahata, M.; Yamaguchi, K. *J. Org. Chem.* **2006**, *71*, 6600–6603.
- (6) Grimmett, M.R. In *Comprehensive Heterocyclic Chemistry II*; Katritzky, A.R., Rees, C.W., Scriven, E.F.V., Eds.; Pergamon Press: New York, 1996; Vol. 3, pp 77–220.
- (7) Greenhill, J.V.; Lue, L. In *Progress in Medicinal Chemistry*; Ellis, G.P., Luscombe, D.K., Eds.; Elsevier Science: New York, 1993; Vol. 30, pp 170–175.
- (8) Shadizadeh, F.; Shafiee, A.; Kazemi, R.; Mahammadi, M. *Ind. J. Chem.* **2002**, *41B*, 2679–2682.
- (9) Bromne, T.R.; Szabo, G.K. *J. Clin. Pharmacol.* **1989**, *29*, 1–270.
- (10) Hadizadeh, F.; Mehri, N. *J. Heterocycl. Chem.* **2006**, *43*, 112–119.
- (11) Flosi, W.J.; DeGoey, D.A.; Grampovnik, D.J.; Chen, H.; Klein, L.L.; Dekhtyar, T.; Masse, S.; Marsh, K.C.; Mo, K.M.; Kempf, D. *Bioorg. Med. Chem. Lett.* **2006**, *14*, 6695–6712.
- (12) Balasubramanian, M.; D'Souza, A. *Tetrahedron* **1968**, *24*, 5399–5408.
- (13) Gopalakrishnan, M.; Sureshkumar, P.; Thanusu, J.; Prabhu, C.; Kanagarajan, V. *J. Chem. Res.* **2007**, *2*, 80–81.
- (14) Gopalakrishnan, M.; Sureshkumar, P.; Kanagarajan, V.; Thanusu, J.; Govindaraju, R. *J. Chem. Res.* **2005**, *5*, 299–303.
- (15) Gopalakrishnan, M.; Thanusu, J.; Kanagarajan, V. *J. Korean Chem. Soc.* **2008**, *52*, 47–51.
- (16) Gopalakrishnan, M.; Kanagarajan, V.; Thanusu, J. *Green Chem. Lett. Rev.* **2008**, *1*, 241–246.
- (17) Gopalakrishnan, M.; Sureshkumar, P.; Kanagarajan, V.; Thanusu, J. *J. Korean Chem. Soc.* **2007**, *51*, 346–351.
- (18) Gopalakrishnan, M.; Sureshkumar, P.; Kanagarajan, V.; Thanusu, J. *Lett. Org. Chem.* **2005**, *2*, 444–446.
- (19) Gopalakrishnan, M.; Sureshkumar, P.; Thanusu, J.; Kanagarajan, V.; Govindaraju, R.; Ezhilarasi, M.R. *Lett. Org. Chem.* **2006**, *3*, 484–488.
- (20) Gopalakrishnan, M.; Sureshkumar, P.; Thanusu, J.; Kanagarajan, V. *Chem. Heterocycl. Comp.* **2008**, *44*, 950–955.
- (21) Gopalakrishnan, M.; Sureshkumar, P.; Thanusu, J.; Kanagarajan, V. *J. Enzyme Inhib. Med. Chem.* **2008**, *23*, 974–979.
- (22) Gopalakrishnan, M.; Sureshkumar, P.; Thanusu, J.; Kanagarajan, V. *J. Enzyme Inhib. Med. Chem.* **2008**, *23*, 347–351.
- (23) Das, S.; Thakur, A.J. *Green Chem. Lett. Rev.* **2011**, *4*, 131–135.
- (24) Hayashi, T.; Kishi, E.; Soloshonok, V.A.; Uozumi, Y. *Tetrahedron Lett.* **1996**, *37*, 4969–4972.
- (25) Dahlstrom, M.; Lindgren, F.; Berntsson, K.M.; Sjogren, M.; Martensson, L.G.E.; Jonsson, P.R.; Elwing, H. *J. Exp. Zool. Part A Comp. Exp. Biol.* **2005**, *303*, 551–562.
- (26) Zavala, J.A.; Pereira, E.R.; Zetola, V.H.; Teive, H.A.; Novak, E.M.; Werneck, L.C. *Arq. Neuropsiquiatr.* **2004**, *62*, 889–891.
- (27) Silverman, R.B. Enzyme Inhibition and Inactivation. In *The Organic Chemistry of Drug Design and Drug Action*; Academic Press, New York: San Diego, CA, 1992; pp 181–185.
- (28) Martin, K.J.; Chen, S.F.; Clark, G.M.; Degen, D.; Wayima, M.; Von Hoff, D.D.; Kaddurach-Daouk, R. *J. Natl. Cancer Inst.* **1994**, *86*, 608–613.